Liisa Bayko
Stock Analyst at Evercore ISI Group
(4.17)
# 565
Out of 4,415 analysts
59
Total ratings
45.76%
Success rate
16.63%
Average return
Main Sectors:
Top Industries:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals | Maintains: Outperform | $25 → $30 | $19.38 | +54.80% | 2 | Apr 24, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $438 | $400.16 | +9.46% | 13 | Apr 11, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $325 → $405 | $216.05 | +87.46% | 8 | Mar 20, 2024 | |
| ETNB 89bio | Maintains: Outperform | $29 → $37 | $8.86 | +317.61% | 3 | Mar 7, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: In-Line | n/a | $2.54 | - | 2 | Feb 12, 2024 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $30 → $14 | $6.16 | +127.27% | 4 | Sep 22, 2023 | |
| AKRO Akero Therapeutics | Maintains: Outperform | $50 → $60 | $19.71 | +204.41% | 2 | Sep 13, 2023 | |
| CARM Carisma Therapeutics | Initiates: Outperform | $12 | $1.60 | +650.00% | 1 | Jul 6, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $60 → $80 | $43.20 | +85.19% | 5 | Jun 6, 2023 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Outperform | $13 → $10 | $4.48 | +123.21% | 4 | Apr 20, 2023 | |
| ATXS Astria Therapeutics | Initiates: Outperform | $18 | $9.35 | +92.51% | 1 | Mar 28, 2023 | |
| ALT Altimmune | Maintains: Outperform | $14 → $25 | $7.19 | +247.71% | 1 | Jan 18, 2023 | |
| ENTA Enanta Pharmaceuticals | Upgrades: Outperform | $62 | $13.91 | +345.72% | 4 | Jul 6, 2022 | |
| CRSP CRISPR Therapeutics AG | Downgrades: In-Line | $66 → $60 | $55.07 | +8.95% | 1 | Jun 23, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $7.77 | - | 1 | Nov 23, 2021 | |
| EDIT Editas Medicine | Upgrades: Outperform | n/a | $5.62 | - | 1 | Aug 5, 2021 | |
| AVTE Aerovate Therapeutics | Initiates: Outperform | n/a | $20.75 | - | 1 | Jul 26, 2021 | |
| VERA Vera Therapeutics | Initiates: Outperform | n/a | $43.50 | - | 1 | Jun 8, 2021 | |
| TBIO Telesis Bio | Downgrades: In-Line | n/a | $0.35 | - | 1 | Mar 18, 2021 | |
| TBPH Theravance Biopharma | Reinstates: Outperform | n/a | $9.37 | - | 1 | Nov 24, 2020 | |
| ABUS Arbutus Biopharma | Upgrades: Market Outperform | n/a | $2.68 | - | 1 | Feb 5, 2020 | |
| SVRA Savara | Initiates: Market Outperform | n/a | $4.68 | - | 1 | Sep 11, 2017 |
Kiniksa Pharmaceuticals
Apr 24, 2024
Maintains: Outperform
Price Target: $25 → $30
Current: $19.38
Upside: +54.80%
Vertex Pharmaceuticals
Apr 11, 2024
Upgrades: Outperform
Price Target: $438
Current: $400.16
Upside: +9.46%
Madrigal Pharmaceuticals
Mar 20, 2024
Maintains: Outperform
Price Target: $325 → $405
Current: $216.05
Upside: +87.46%
89bio
Mar 7, 2024
Maintains: Outperform
Price Target: $29 → $37
Current: $8.86
Upside: +317.61%
AN2 Therapeutics
Feb 12, 2024
Downgrades: In-Line
Price Target: n/a
Current: $2.54
Upside: -
Travere Therapeutics
Sep 22, 2023
Maintains: Outperform
Price Target: $30 → $14
Current: $6.16
Upside: +127.27%
Akero Therapeutics
Sep 13, 2023
Maintains: Outperform
Price Target: $50 → $60
Current: $19.71
Upside: +204.41%
Carisma Therapeutics
Jul 6, 2023
Initiates: Outperform
Price Target: $12
Current: $1.60
Upside: +650.00%
Ultragenyx Pharmaceutical
Jun 6, 2023
Upgrades: Outperform
Price Target: $60 → $80
Current: $43.20
Upside: +85.19%
BioCryst Pharmaceuticals
Apr 20, 2023
Maintains: Outperform
Price Target: $13 → $10
Current: $4.48
Upside: +123.21%
Astria Therapeutics
Mar 28, 2023
Initiates: Outperform
Price Target: $18
Current: $9.35
Upside: +92.51%
Altimmune
Jan 18, 2023
Maintains: Outperform
Price Target: $14 → $25
Current: $7.19
Upside: +247.71%
Enanta Pharmaceuticals
Jul 6, 2022
Upgrades: Outperform
Price Target: $62
Current: $13.91
Upside: +345.72%
CRISPR Therapeutics AG
Jun 23, 2022
Downgrades: In-Line
Price Target: $66 → $60
Current: $55.07
Upside: +8.95%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.77
Upside: -
Editas Medicine
Aug 5, 2021
Upgrades: Outperform
Price Target: n/a
Current: $5.62
Upside: -
Aerovate Therapeutics
Jul 26, 2021
Initiates: Outperform
Price Target: n/a
Current: $20.75
Upside: -
Vera Therapeutics
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $43.50
Upside: -
Telesis Bio
Mar 18, 2021
Downgrades: In-Line
Price Target: n/a
Current: $0.35
Upside: -
Theravance Biopharma
Nov 24, 2020
Reinstates: Outperform
Price Target: n/a
Current: $9.37
Upside: -
Arbutus Biopharma
Feb 5, 2020
Upgrades: Market Outperform
Price Target: n/a
Current: $2.68
Upside: -
Savara
Sep 11, 2017
Initiates: Market Outperform
Price Target: n/a
Current: $4.68
Upside: -